Which statement about look-alike/sound-alike (LASA) drugs is accurate?

• A. Tall man lettering helps prevent LASA errors
• B. LASA issues are eliminated by double-checks
• C. LASA concerns only brand-name drugs
• D. LASA has no impact on patient safety

Answer: (A)

Look-alike/sound-alike names create a real risk of medication errors, and tall man lettering is a practical way to reduce that risk. By capitalizing distinct parts of a drug name, tall man lettering makes the differences between look-alike names stand out at a glance. This helps pharmacists, nurses, and other clinicians notice the correct product during prescribing, dispensing, labeling, and administration, especially in busy or high-stress environments.

This approach is part of a broader patient-safety strategy and does not claim to eliminate all LASA risks by itself. Double-checks can catch some mistakes, but they’re not foolproof and don’t replace the usefulness of clearer name presentation. LASA concerns involve both brand-name and generic-name drugs, and they do impact patient safety, so it would be inaccurate to claim there’s no effect.